Jane Street Group LLC Sells 115,722 Shares of Seer, Inc. (NASDAQ:SEER)

Jane Street Group LLC reduced its holdings in shares of Seer, Inc. (NASDAQ:SEER) by 37.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 190,317 shares of the company’s stock after selling 115,722 shares during the quarter. Jane Street Group LLC’s holdings in Seer were worth $375,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. AQR Capital Management LLC bought a new position in shares of Seer during the second quarter valued at $30,000. Point72 DIFC Ltd bought a new position in shares of Seer during the second quarter valued at $35,000. American Century Companies Inc. lifted its holdings in shares of Seer by 42.1% during the second quarter. American Century Companies Inc. now owns 61,752 shares of the company’s stock valued at $104,000 after purchasing an additional 18,302 shares in the last quarter. Quadrature Capital Ltd lifted its holdings in shares of Seer by 301.7% during the third quarter. Quadrature Capital Ltd now owns 57,088 shares of the company’s stock valued at $112,000 after purchasing an additional 42,875 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Seer during the second quarter valued at $133,000. 75.20% of the stock is owned by institutional investors.

Seer Price Performance

Shares of NASDAQ:SEER opened at $2.41 on Thursday. Seer, Inc. has a 1 year low of $1.51 and a 1 year high of $2.63. The stock’s fifty day moving average price is $2.34 and its 200-day moving average price is $1.98. The company has a market cap of $142.11 million, a P/E ratio of -1.85 and a beta of 1.57.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.